Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: A-802710; BL 194; CT-1501R; ProTec

Latest Information Update: 10 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cell Therapeutics
  • Developer DiaKine Therapeutics; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases
  • Class Adjuvants; Chemoprotectants; Nonsteroidal anti-inflammatories; Radiation-sensitising agents; Small molecules; Xanthines
  • Mechanism of Action Immunosuppressants; Interleukin 12 inhibitors; Lysophosphatidic acid acyltransferase inhibitors; STAT4 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute lung injury; Chemotherapy-induced damage; Graft-versus-host disease; Mucositis; Neutropenia; Septic shock; Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 10 Jul 2019 Discontinued - Phase-III for Transplant rejection (Adjunctive treatment) in USA (IV)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Sep 2014 The NIH completes a phase II trial in islet cell transplantation (Adjunctive treatment) in the US (NCT00464555)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top